Genmab A/S

CPSE:GMAB Aktierapport

Börsvärde: DKK 95.5b

Genmab Framtida tillväxt

Future kriterier kontrolleras 3/6

Genmab förväntas öka intäkter och intäkter med 18.6% respektive 11.5% per år. EPS förväntas tillväxt med 18.3% per år. Avkastningen på eget kapital förväntas bli 17.1% om 3 år.

Viktig information

18.6%

Tillväxttakt i vinsten

18.27%

Tillväxttakt för EPS

Biotechs vinsttillväxt22.8%
Intäkternas tillväxttakt11.5%
Framtida avkastning på eget kapital17.08%
Bevakning av analytiker

Good

Senast uppdaterad15 Jun 2026

Senaste uppdateringarna om framtida tillväxt

Analysartikel • May 11

Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...

Recent updates

Uppdatering av berättelse • Jun 10

GMAB: 2026 Readouts And Commercial Pivot Will Shape Bullish Outlook

Genmab’s consensus analyst price target has been reset lower from DKK 2,233 to DKK 2,313, with analysts citing a more commercially focused platform, evolving assumptions for revenue growth and margins, and updated P/E expectations following recent research on key pipeline readouts and price target revisions. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the product pipeline and caution around valuation assumptions and execution risks.
Uppdatering av berättelse • May 26

GMAB: Late Stage Oncology Readouts Will Support Stronger Margins And Earnings Quality

Genmab's analyst price target has been trimmed slightly to DKK 3,000, as analysts factor in more measured revenue growth expectations, a modestly higher discount rate, and a somewhat richer forward P/E outlook. They are still pointing to solid margin potential and recent bullish rating updates from several firms.
Analysartikel • May 15

There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings

The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...
Analysartikel • May 11

Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...
Uppdatering av berättelse • Apr 29

GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook

Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
Uppdatering av berättelse • Apr 15

GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook

Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.
Uppdatering av berättelse • Mar 31

GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile

Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.
Uppdatering av berättelse • Mar 17

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
Uppdatering av berättelse • Mar 03

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
Uppdatering av berättelse • Feb 17

GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook

Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.
Uppdatering av berättelse • Feb 02

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
Uppdatering av berättelse • Jan 19

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
Uppdatering av berättelse • Jan 05

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
Uppdatering av berättelse • Dec 14

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
Uppdatering av berättelse • Nov 29

GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook

Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.
Uppdatering av berättelse • Nov 15

GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance

Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.
Uppdatering av berättelse • Nov 01

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain

Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.
Uppdatering av berättelse • Oct 18

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.
Uppdatering av berättelse • Oct 04

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.
Analysartikel • Sep 24

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Uppdatering av berättelse • Sep 04

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.
Analysartikel • Jul 31

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
User avatar
Ny berättelse • Nov 11

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

Prognoser för vinst- och omsättningstillväxt

CPSE:GMAB - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20286,0741,6362,3952,04718
12/31/20275,0241,0881,4451,24121
12/31/20264,28573095082422
3/31/20263,901821872902N/A
12/31/20253,7209631,1311,186N/A
9/30/20253,8461,5831,2941,369N/A
6/30/20253,6471,3711,0551,134N/A
3/31/20253,2331,1361,1241,194N/A
12/31/20243,1211,1331,0821,126N/A
9/30/20242,9647029801,005N/A
6/30/20242,743798939971N/A
3/31/20242,576791775818N/A
1/1/20242,3906311,0171,071N/A
9/30/20232,389590806866N/A
6/30/20232,378680826885N/A
3/31/20232,216757902955N/A
12/31/20222,088785518563N/A
9/30/20221,580745459495N/A
6/30/20221,438558277315N/A
3/31/20221,342354201242N/A
12/31/20211,288452302341N/A
9/30/20211,232448148185N/A
6/30/20211,168401894928N/A
3/31/20211,703880856899N/A
12/31/20201,6607811,0061,056N/A
9/30/20201,7368891,1221,166N/A
6/30/20201,559853357399N/A
3/31/2020837349361383N/A
12/31/2019806325N/A199N/A
9/30/2019532223N/A198N/A
6/30/2019487178N/A190N/A
3/31/2019441202N/A180N/A
12/31/2018464226N/A156N/A
9/30/2018437222N/A165N/A
6/30/2018397194N/A140N/A
3/31/2018462213N/A215N/A
12/31/2017381178N/A256N/A
9/30/2017361184N/A200N/A
6/30/2017356208N/A218N/A
3/31/2017272174N/A156N/A
12/31/2016257168N/A46N/A
9/30/2016221111N/A99N/A
6/30/2016205102N/A88N/A
3/31/201618382N/A55N/A
12/31/2015165111N/A45N/A
9/30/201511666N/A10N/A
6/30/201511569N/A3N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: GMAB s prognostiserade vinsttillväxt ( 18.6% per år) är över sparkvoten ( 2% ).

Resultat vs marknad: GMAB s intäkter ( 18.6% per år) förväntas växa snabbare än marknaden för Danish ( 8.6% per år).

Höga tillväxtresultat: GMAB s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: GMAB s intäkter ( 11.5% per år) förväntas växa snabbare än Danish marknaden ( 3.7% per år).

Hög tillväxtintäkter: GMAB s intäkter ( 11.5% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: GMAB s avkastning på eget kapital förväntas bli låg om 3 år ( 17.1 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/06/16 05:51
Aktiekurs vid dagens slut2026/06/16 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Genmab A/S bevakas av 39 analytiker. 22 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays